Background: pandemic and vaccine
The COVID-19 pandemic was declared by the WHO on 11 March 2020 and Italy was the first country after China to be affected, counting, on 21 December 2020, 1.952.305 cases and 66.717 deaths [1].
During 2020, a huge scientific, organizational and economic effort has led to the availability of vaccines directed against SARS-CoV-2. Despite the acceleration of development, evaluation and approval times, these vaccines are effective, safe and of good quality to fight the pandemic. In Europe, four vaccines will come into use after approval by the European Medicines Agency (EMA): 2 mRNA vaccines containing genetic instructions to induce an immune response against coronavirus (BNT162b2; mRNA-1273) and 2 viral vector vaccines using harmless adenoviruses (ChAdOx1-SARS-CoV-2; Ad26.COV2.S) [2].
Anzeige
The public health strategies currently implemented at the international level imply the administration of the vaccine primarily to groups of population most at risk such as healthcare professionals and individuals aged 65 and over. The severity of the pandemic, however, led to shorten the development and evaluation period of COVID-19 vaccines and suggested an emergency regulatory authorization procedure. This acceleration has so far prevented from obtaining enough information on the safety of the COVID-19 among specific population groups such as children and adolescents less than 16 years, pregnant women and nursing women [3].
Compatibility between breastfeeding and COVID-19 vaccination: indications from non-EU countries
UK. Initially, breastfeeding women, especially those belonging to the National Health Service (NHS), have been faced with the choice between continuing to breastfeed or postponing vaccination (“wait until you have finished breastfeeding before vaccinating yourself”) [4]. Instead, the UK Joint Committee on Vaccination and Immunization (JCVI) now advises that although “there is lack of safety data for these specific vaccinations in breastfeeding”, there is no known risk in giving these vaccines to breastfeeding women. Ultimately, “breastfeeding women should therefore be offered vaccination if they are otherwise eligible
” [5, 6].Canada. The Canadian Pfizer-BioNTech vaccine manufacturer sheet simply points out that it is not known whether the vaccine is excreted in human milk and that a risk to the newborn and infant cannot be excluded [7].
USA. The Food and Drugs Administration (FDA) [8, 9] and the Centers for Disease Control and Prevention (CDC) [10], rather than on the existence of a true contraindication, have emphasized the absence of scientific data: “no data are available to evaluate the effects of the Pfizer-BioNTech COVID-19 vaccine on the breast-fed infant or on milk production / excretion”. This position de facto leaves open the possibility of breastfeeding women being vaccinated. In fact:
-
The US Society for Maternal-Fetal Medicine (SMFM) states that “the vaccine should be offered to women who are breastfeeding” and “are suitable in every other respect” [11];
-
The American College of Obstetricians and Gynecologists (ACOG) recommends that COVID-19 vaccination also be offered to breastfeeding women, without the need to avoid vaccination or stop breastfeeding [12].
-
The Academy of Breastfeeding Medicine (ABM) points out that “it is unlikely that the lipid component of the vaccine enters the bloodstream and reaches the breast tissue. If so, it is even less likely that an intact nanoparticle or mRNA will pass into the milk “ [13]. In the unlikely event that mRNA is found in milk, one would expect it to be digested by the baby without having any biological effect. In addition, the ABM notes, vaccination in breastfeeding would allow the passage from mother to infant of specific IgA antibodies against SARS-CoV-2 within 5–7 days [2].
Anzeige
EU. On 21 December 2020, the Committee for Medicinal Products for Use in Humans (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the safety and efficacy of the COVID-19 mRNA (Comirnaty) vaccine in the population aged 16 years and over. The EMA underlines that the vaccine mRNA is rapidly destroyed after the administration of the vaccine. The vaccine can be administered also to those with possible previous asymptomatic SARS-CoV-2 infection and to immunocompromised patients. Although data relating to the use of the vaccine during pregnancy are very limited, actually animal studies do not show dangerous effects. The decision whether or not to vaccinate during pregnancy should be made after consulting health professionals and assessing benefits and risks. Although currently no lactation study is ongoing, according to EMA no specific risk is expected for the breastfeeding mother and her/his nursed infant [14]. Finally, according to the manufacturer sheet, it is not known whether Comirnaty is excreted in human milk [15] and the breastfeeding woman is invited to refer to healthcare personnel. The Italian Medicines Agency has confirmed EMA’s indications [16].
Compatibility between breastfeeding and COVID-19 vaccination: ad interim indications of the Italian scientific societies
On the basis of the above, a joint ad hoc Working Group of the Italian Society of Neonatology (SIN), the Italian Society of Pediatrics (SIP), the Italian Society of Perinatal Medicine (SIMP), the Italian Society of Obstetrics and Gynecology (SIGO), the Italian Association of Hospital Obstetricians-Gynecologists (AOGOI) and the Italian Society of Infectious and Tropical Diseases (SIMIT) have focused the issue of COVID-19 vaccination while breastfeeding. Between December 14 and 30, 2020 a facilitator gathered the appropriate knowledge, synthetized and balanced the varied opinions and suggestions from the other members of the Working Group. A general unanimous agreement on a preliminary draft was achieved by online communications from the entire panel. Eventually, the final version of the position statement has been approved by the Executive Committees of the adhering Scientific Societies.
Regarding the compatibility between breastfeeding and COVID-19 vaccination, the Italian Scientific Societies affirm that:
-
Breastfeeding women should not be systematically invited to stop breastfeeding in order to be vaccinated against COVID-19 [22]. In fact, the decision whether or not to administer the COVID-19 vaccine to the breastfeeding woman should be made after mutual agreement between her and the health professionals, taking into account specific health, social, familiar and work conditions.
-
Biological plausibility suggests that in a breastfed baby the risk resulting from the mother’s COVID-19 vaccination is extremely low, while on the other hand, interruption of breastfeeding would lead to a certain loss of its well-documented benefits [23].
-
Pregnant and lactating women should be included in future vaccination trials, particularly because pregnancy increases susceptibility to or severity of a disease [24] and because it represents a possible approach to protect the infant in the first months of life, following the transplacental transfer of anti-SARS-CoV-2 IgG antibodies [25].
-
In conclusion, COVID-19 vaccination is currently considered compatible with breastfeeding.
Acknowledgments
Not applicable.
Ethics approval and consent to participate
Not applicable.
Competing interests
None of the Authors declares a conflict of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.